Entos to commence Phase II Covid-19 vaccine trial in South Africa

Entos Pharmaceuticals has obtained approval from the South African Health Products Regulatory Authority (SAHPRA) to commence a Phase II clinical trial of its Covid-19 vaccine candidate, Covigenix VAX-001, in the country. Made using the Entos’ Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, the deoxyribonucleic acid (DNA) vaccine encodes the SARS-CoV-2 Spike protein. It also includes two genetic adjuvants to induce the innate and adaptive immune systems, offering efficient and long-term protection from Covid-19.